Hofseth BioCare ASA

BATS-CHIXE:HBCO Stock Report

Market Cap: NOK 1.1b

Hofseth BioCare Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jon Odegard

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2yrs
Board average tenure2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Odegard's remuneration changed compared to Hofseth BioCare's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-NOK 140m

Dec 31 2022n/an/a

-NOK 137m

Sep 30 2022n/an/a

-NOK 136m

Jun 30 2022n/an/a

-NOK 139m

Mar 31 2022n/an/a

-NOK 135m

Dec 31 2021n/an/a

-NOK 126m

Sep 30 2021n/an/a

-NOK 120m

Jun 30 2021n/an/a

-NOK 115m

Mar 31 2021n/an/a

-NOK 111m

Dec 31 2020NOK 2mNOK 695k

-NOK 102m

Sep 30 2020n/an/a

-NOK 104m

Jun 30 2020n/an/a

-NOK 90m

Mar 31 2020n/an/a

-NOK 86m

Dec 31 2019NOK 2mNOK 660k

-NOK 89m

Sep 30 2019n/an/a

-NOK 79m

Jun 30 2019n/an/a

-NOK 81m

Mar 31 2019n/an/a

-NOK 83m

Dec 31 2018NOK 2mNOK 702k

-NOK 85m

Sep 30 2018n/an/a

-NOK 74m

Jun 30 2018n/an/a

-NOK 66m

Mar 31 2018n/an/a

-NOK 66m

Dec 31 2017NOK 2mNOK 2m

-NOK 16m

Sep 30 2017n/an/a

-NOK 28m

Jun 30 2017n/an/a

-NOK 60m

Mar 31 2017n/an/a

-NOK 92m

Dec 31 2016NOK 2mNOK 2m

-NOK 147m

Compensation vs Market: Insufficient data to establish whether Jon's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Odegard

less than a year

Tenure

NOK 1,701,000

Compensation

Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Odegard
Chief Executive Officerless than a yearNOK 1.70mno data
Bomi Framroze
Chief Scientific Officer13.4yrsNOK 21.73m1.32%
NOK 14.3m
James Berger
Chief Commercial Officer2.3yrsNOK 7.81mno data
Angelika Florvaag
Chief Quality Officer2.3yrsNOK 822.00kno data
Christel Kanli
CFO & COOless than a yearno datano data
Crawford Currie
Head of Medical R&D and Directorno datano data0.19%
NOK 2.1m
Tanja Schaffer
EVP of Global Ingredients Division & CEO of HBC Switzerland GmbH1.8yrsno datano data

2.0yrs

Average Tenure

Experienced Management: HBCO's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Crawford Currie
Head of Medical R&D and Director1.4yrsno data0.19%
NOK 2.1m
Roger Hofseth
Directorless than a yearno data17.59%
NOK 191.1m
Amy Novogratz
Independent Director1.5yrsno datano data
Christoph Baldegger
Independent Director8.4yrsNOK 96.00k0.20%
NOK 2.2m
Torill Eliassen
Independent Director8yrsNOK 116.00k0.051%
NOK 550.0k
Kristin Grung
Independent Chair of the Board2.5yrsno datano data

2.0yrs

Average Tenure

49yo

Average Age

Experienced Board: HBCO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/27 18:12
End of Day Share Price 2023/03/30 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hofseth BioCare ASA is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonas PeciulisNorne Securities AS
Henning SteffenrudSwedbank Norway